NO340794B1 - Farmasøytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre - Google Patents
Farmasøytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre Download PDFInfo
- Publication number
- NO340794B1 NO340794B1 NO20082848A NO20082848A NO340794B1 NO 340794 B1 NO340794 B1 NO 340794B1 NO 20082848 A NO20082848 A NO 20082848A NO 20082848 A NO20082848 A NO 20082848A NO 340794 B1 NO340794 B1 NO 340794B1
- Authority
- NO
- Norway
- Prior art keywords
- hyaluronic acid
- acid
- salts
- kda
- mixture according
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 44
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 34
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 34
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960002286 clodronic acid Drugs 0.000 title claims abstract description 28
- 201000008482 osteoarthritis Diseases 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 29
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 16
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 claims description 13
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 10
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000470 constituent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000003442 weekly effect Effects 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 6
- 229940122361 Bisphosphonate Drugs 0.000 description 5
- 150000004663 bisphosphonates Chemical class 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 241000219061 Rheum Species 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000005065 subchondral bone plate Anatomy 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 229940018991 hyalgan Drugs 0.000 description 3
- 229940099552 hyaluronan Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940053210 supartz Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940072322 hylan Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940023593 orthovisc Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229940036220 synvisc Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002515A ITMI20052515A1 (it) | 2005-12-29 | 2005-12-29 | Formulazione farmaceutica per il trattamento della osteoartrite |
| PCT/EP2006/012367 WO2007073921A1 (en) | 2005-12-29 | 2006-12-21 | Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20082848L NO20082848L (no) | 2008-08-27 |
| NO340794B1 true NO340794B1 (no) | 2017-06-19 |
Family
ID=36648609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082848A NO340794B1 (no) | 2005-12-29 | 2008-06-26 | Farmasøytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20090042833A1 (enExample) |
| EP (1) | EP1976538B1 (enExample) |
| JP (1) | JP2009522218A (enExample) |
| KR (2) | KR20140107651A (enExample) |
| AT (1) | ATE446763T1 (enExample) |
| AU (1) | AU2006331019B2 (enExample) |
| CA (1) | CA2646974C (enExample) |
| CY (1) | CY1109541T1 (enExample) |
| DE (1) | DE602006010111D1 (enExample) |
| DK (1) | DK1976538T3 (enExample) |
| ES (1) | ES2333615T3 (enExample) |
| IT (1) | ITMI20052515A1 (enExample) |
| NO (1) | NO340794B1 (enExample) |
| NZ (1) | NZ569420A (enExample) |
| PL (1) | PL1976538T3 (enExample) |
| PT (1) | PT1976538E (enExample) |
| RU (1) | RU2414908C2 (enExample) |
| SI (1) | SI1976538T1 (enExample) |
| WO (1) | WO2007073921A1 (enExample) |
| ZA (1) | ZA200805598B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011311859B2 (en) * | 2010-10-07 | 2015-06-04 | National Cheng Kung University | Use of hyaluronan for promoting angiogenesis |
| AU2015343845B2 (en) | 2014-11-07 | 2018-11-08 | Exostemtech Co., Ltd. | Composition for differentiation induction of adipocyte containing stem cell-derived exosome, regeneration of adipose tissue, and skin whitening or wrinkle improvement |
| KR101706642B1 (ko) | 2015-02-04 | 2017-02-17 | 주식회사 엑소스템텍 | 연골세포로 분화되고 있는 줄기세포로부터 추출된 엑소좀을 포함하는 연골세포 분화 유도 또는 연골조직 재생용 조성물 |
| IT201600123773A1 (it) * | 2016-12-06 | 2018-06-06 | Abiogen Pharma Spa | Composizione per il trattamento dell’osteoartrosi |
| IT202100023894A1 (it) * | 2021-09-16 | 2023-03-16 | Professional Derma Sa | Composizione per utilizzo in campo ortopedico |
| EP4450062A1 (en) * | 2023-04-20 | 2024-10-23 | Abiogen Pharma S.p.A. | Composition for the treatment of osteoarthrosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1187828B (it) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi |
| JP2001253827A (ja) * | 2000-02-15 | 2001-09-18 | Pfizer Prod Inc | 骨粗鬆症を治療するための組成物および方法 |
| KR100492110B1 (ko) * | 2000-05-05 | 2005-06-02 | 에프. 호프만-라 로슈 아게 | 비스포스폰산 또는 그의 염을 포함하는 피하 투여용겔-유사 약학 조성물 |
| US20050287135A1 (en) * | 2002-05-17 | 2005-12-29 | Wyeth | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
| KR100648515B1 (ko) * | 2004-05-04 | 2006-11-27 | (주)아모레퍼시픽 | 비스포스포네이트-함유 고분자 미립구를 포함하는 골-관련질환 치료 또는 예방용 서방 효과를 갖는 주사제 |
-
2005
- 2005-12-29 IT IT002515A patent/ITMI20052515A1/it unknown
-
2006
- 2006-12-21 DK DK06841087T patent/DK1976538T3/da active
- 2006-12-21 WO PCT/EP2006/012367 patent/WO2007073921A1/en not_active Ceased
- 2006-12-21 PT PT06841087T patent/PT1976538E/pt unknown
- 2006-12-21 ES ES06841087T patent/ES2333615T3/es active Active
- 2006-12-21 CA CA2646974A patent/CA2646974C/en active Active
- 2006-12-21 AT AT06841087T patent/ATE446763T1/de active
- 2006-12-21 NZ NZ569420A patent/NZ569420A/en unknown
- 2006-12-21 PL PL06841087T patent/PL1976538T3/pl unknown
- 2006-12-21 US US12/159,222 patent/US20090042833A1/en not_active Abandoned
- 2006-12-21 SI SI200630473T patent/SI1976538T1/sl unknown
- 2006-12-21 AU AU2006331019A patent/AU2006331019B2/en active Active
- 2006-12-21 KR KR1020147021224A patent/KR20140107651A/ko not_active Abandoned
- 2006-12-21 RU RU2008126108/15A patent/RU2414908C2/ru active
- 2006-12-21 JP JP2008547886A patent/JP2009522218A/ja active Pending
- 2006-12-21 EP EP06841087A patent/EP1976538B1/en active Active
- 2006-12-21 ZA ZA200805598A patent/ZA200805598B/xx unknown
- 2006-12-21 DE DE602006010111T patent/DE602006010111D1/de active Active
-
2008
- 2008-06-26 NO NO20082848A patent/NO340794B1/no unknown
- 2008-06-26 KR KR1020087015583A patent/KR101470608B1/ko active Active
-
2009
- 2009-12-03 CY CY20091101271T patent/CY1109541T1/el unknown
-
2014
- 2014-09-03 US US14/476,521 patent/US9943540B2/en active Active
-
2018
- 2018-02-28 US US15/907,300 patent/US20180185407A1/en not_active Abandoned
-
2019
- 2019-12-27 US US16/728,378 patent/US20200147126A1/en not_active Abandoned
Non-Patent Citations (3)
| Title |
|---|
| COCCO R., et al, Effects of clodronate on synovial fluid levels of some inflammatory mediators, after intra-articular administration to patients with synovitis secondary to knee osteoarthritis, Boll Soc Ital Biol Sper. 1999 Nov-Dec;75(11-12):71-6., Dated: 01.01.0001 * |
| LOHMANDER L. S., et. al., Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group, Ann Rheum Dis. 1996 Jul; 55(7): 424–431., Dated: 01.01.0001 * |
| PAGNANO M,. Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans, Osteoarthritis Cartilage. 2005 Sep;13(9):751-61., Dated: 01.01.0001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20082848L (no) | 2008-08-27 |
| AU2006331019A1 (en) | 2007-07-05 |
| ES2333615T3 (es) | 2010-02-24 |
| AU2006331019A2 (en) | 2009-01-22 |
| RU2008126108A (ru) | 2010-01-10 |
| WO2007073921A1 (en) | 2007-07-05 |
| AU2006331019B2 (en) | 2012-03-22 |
| KR20140107651A (ko) | 2014-09-04 |
| US20140371170A1 (en) | 2014-12-18 |
| JP2009522218A (ja) | 2009-06-11 |
| CA2646974A1 (en) | 2007-07-05 |
| ZA200805598B (en) | 2009-11-25 |
| KR101470608B1 (ko) | 2014-12-09 |
| CY1109541T1 (el) | 2014-08-13 |
| US20180185407A1 (en) | 2018-07-05 |
| KR20080082657A (ko) | 2008-09-11 |
| US20090042833A1 (en) | 2009-02-12 |
| US9943540B2 (en) | 2018-04-17 |
| NZ569420A (en) | 2010-05-28 |
| PT1976538E (pt) | 2009-12-07 |
| EP1976538A1 (en) | 2008-10-08 |
| PL1976538T3 (pl) | 2010-03-31 |
| CA2646974C (en) | 2013-06-11 |
| HK1123986A1 (en) | 2009-07-03 |
| DK1976538T3 (da) | 2010-01-11 |
| ATE446763T1 (de) | 2009-11-15 |
| US20200147126A1 (en) | 2020-05-14 |
| SI1976538T1 (sl) | 2010-01-29 |
| DE602006010111D1 (de) | 2009-12-10 |
| RU2414908C2 (ru) | 2011-03-27 |
| EP1976538B1 (en) | 2009-10-28 |
| ITMI20052515A1 (it) | 2007-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200147126A1 (en) | Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid | |
| Reid et al. | Zoledronate | |
| WO2014207232A4 (en) | Antisense oligomers and conjugates targeting pcsk9 | |
| CA2782122A1 (en) | Compositions and methods for stabilized polysaccharide formulations | |
| JP2016132669A (ja) | 関節を治療するための組成物及び方法 | |
| TWI516269B (zh) | 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物 | |
| MX2008008418A (en) | Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid | |
| HK1123986B (en) | Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid | |
| CN112870217B (zh) | 甘露葡萄糖醛酸多(寡)糖及其硫酸化衍生物在制备治疗骨质疏松症药物中的应用 | |
| NO340249B1 (no) | Sett omfattende bisfosfonat for behandling av høy benomsetning samt anvendelse av bisfosfonat ved slik behandling | |
| P Syddall et al. | Combined therapies of bone disease with bisphosphonates | |
| JP2009522218A5 (enExample) | ||
| EP3334411B1 (en) | Injectable liquid composition for use in the intra-articular infiltration therapy | |
| Pavelka et al. | 326 A MULTICENTRE, INTERNATIONAL, DOUBLE BLIND, RANDOMIZED, PLACEBO–CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF 2 DIFFERENT REGIMENS OF HYADD4-G IN KNEE OSTEOARTHRITIS | |
| US20240066051A1 (en) | Nasal spray using pentosan polysulfate and mucopolysaccharide polysulfate for covid-19 prevention and treatment | |
| Pelletier et al. | TREATMENT WITH CHONDROITIN SULFATE REDUCES CARTILAGE VOLUME LOSS IN KNEE OA PATIENTS ASSESSED BY MRI: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PILOT STUDY | |
| KR20070070215A (ko) | 초-저분자량 헤파린의 신규 용도 | |
| Christensen et al. | 325 EFFICACY OF DIETING OR EXERCISE VS. CONTROL IN OBESE KNEE OSTEOARTHRITIS PATIENTS AFTER A CLINICALLY SIGNIFICANTWEIGHT LOSS: A PRAGMATIC RANDOMIZED CONTROLLED TRIAL | |
| EP4543462A1 (en) | Intra-articular gel for tissue and cartilage regeneration | |
| CN102159218B (zh) | 用于医学用途的新型几丁低聚物组合物 | |
| Petrella et al. | Effect of intra-articular hyaluronic acid agents on subsequent rate of infection following total knee arthroplasty | |
| EP2585078A1 (en) | Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery | |
| Angeli et al. | Pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ): Focus on osteoimmunology | |
| Zhang et al. | Therapeutic RNAi targeting CKIP-1 as a potential bone anabolic strategy | |
| DONATO | GLUCOSAM |